Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan
Peripheral T-cell Lymphoma
DRUG: Systemic therapy
Overall survival (OS), From baseline until date of death from any cause or last known alive date, assessed up to 6 years
Participant baseline demographics, Baseline|Participant baseline clinical characteristics, Baseline|Participant treatment sequence from initial diagnosis, From date of initial diagnosis until death from any cause or last known alive date, assessed up to 6 years|Frequency of treatment regimen by treatment line, End date of each treatment-line of therapy, assessed up to 6 years|Time to next treatment line or death (TTNT), From date of first-line therapy initiation until death from any cause or last known alive date, assessed up to 6 years
The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan